Related Experiment Video
Updated: May 28, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Age- and duration-dependent effects of MPTP on cortical serotonin systems
Twum A Ansah1, Marcus C Ferguson1, Tultul Nayyar1
1Department of Neuroscience and Pharmacology, Meharry Medical College, 1005 D.B. Todd Blvd, Nashville, TN 37208, United States.
Abstract:
It has been well established that aging is the most prominent risk factor for PD. In the MPTP mouse model which has been widely used to study PD, studies have shown that MPTP exhibits its neurotoxic effects on the dopaminergic system in an age-dependent manner. Although it is recognized the serotonergic system is impacted in PD, how aging influences serotonergic neurodegeneration in PD has not been adequately investigated. In the present studies, we examined the long-term effects of MPTP treatment on regional concentrations of dopamine (DA), serotonin (5-HT) and norepinephrine (NE) in the striatum and prefrontal cortex (PFC). We also determined if there are differences in the age-dependent vulnerability of the monoaminergic system to MPTP. In young (3-month-old) mice, MPTP produced significant decreases in striatal DA but no changes in striatal 5-HT and NE three weeks after MPTP treatment. There was partial recovery of striatal DA concentrations 18 months later. This was accompanied by elevated striatal 5-HT. In the PFC, NE was decreased but there was complete recovery 18 months later. By contrast, we observed a long-term decrease in prefrontal 5-HT with no recovery of 5-HT concentrations 18 months after MPTP treatment. Striatal DA and NE but not 5-HT neurons exhibited age-dependent vulnerability to MPTP. Aging had no influence on the neurotoxic effects of MPTP in the PFC. Thus, there is divergence in the response of DA and 5-HT systems to MPTP neurotoxicity.
Insights
Aging influences neurodegeneration in Parkinson's disease (PD) models. MPTP neurotoxicity impacts dopamine and serotonin systems differently based on age, with long-term effects observed in the prefrontal cortex.
Area of Science:
- Neuroscience
- Aging Research
- Neurodegenerative Diseases
Background:
- Aging is the primary risk factor for Parkinson's disease (PD).
- The MPTP mouse model is crucial for studying PD, with MPTP's neurotoxicity showing age-dependent effects on the dopaminergic system.
- The impact of aging on the serotonergic system's neurodegeneration in PD remains under-investigated.
Purpose of the Study:
- To investigate the long-term effects of MPTP on dopamine (DA), serotonin (5-HT), and norepinephrine (NE) concentrations in the striatum and prefrontal cortex (PFC).
- To determine age-dependent differences in the vulnerability of the monoaminergic system to MPTP.
Main Methods:
- MPTP treatment was administered to young mice.
- Regional monoamine concentrations (DA, 5-HT, NE) were measured in the striatum and PFC at different time points post-treatment.
- Age-dependent vulnerability was assessed by comparing responses in young versus aged contexts.
Main Results:
- In young mice, MPTP caused acute striatal DA decrease, with partial recovery and elevated striatal 5-HT after 18 months.
- PFC exhibited decreased NE with full recovery, but a persistent decrease in 5-HT without recovery 18 months post-MPTP.
- Striatal DA and NE neurons showed age-dependent vulnerability, while PFC monoaminergic systems were not influenced by aging.
Conclusions:
- MPTP neurotoxicity affects DA and 5-HT systems distinctly, with aging influencing vulnerability differently across brain regions.
- Long-term serotonergic deficits were observed in the PFC, suggesting a divergence in the response of DA and 5-HT systems to MPTP neurotoxicity.
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Drugs Affecting Neurotransmitter Synthesis
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
